Why BlueWind Medical’s $47.8m raise matters for the next phase of UUI treatment
UUI devices have clinical momentum. BlueWind Medical’s next challenge is proving Revi can scale through access, reimbursement, and workflow adoption.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Is Butterfly Medical’s prostate retraction device the next challenger in minimally invasive BPH treatment?
BPH care needs options beyond pills and surgery. Butterfly Medical’s $21m raise puts its reversible prostate implant in the spotlight.
Medical Devices & Diagnostics
HistoSonics is taking histotripsy beyond liver tumors. Kidney cancer care may be the next credibility test.
HistoSonics has liver clearance. Kidney tumors are the harder test, where non-invasive ambition must meet regulatory and clinical proof.
Medical Devices & Diagnostics
Did Aurie just crack the one-use catheter problem hospitals avoided for decades?
Single-use catheters finally face a regulated reuse challenge. Aurie’s FDA De Novo win could shift urology device economics.
Medical Devices & Diagnostics
Can Biozen turn cuffless blood pressure from medtech promise into clinical reality?
Cuffs are accurate but inconvenient. Biozen’s FDA-cleared BP1000 tests whether fingertip blood pressure checks can change hypertension care.
Medical Devices & Diagnostics
How Envoy Medical, Inc.’s FDA pathway could influence the future of implantable hearing systems
Could fully implanted cochlear implants transform hearing restoration? Explore the regulatory, clinical, and market implications now.
Medical Devices & Diagnostics
Can Mevion’s S250-FIT make proton therapy practical for more cancer centers?
Proton therapy has long had an infrastructure problem. Mevion’s S250-FIT asks whether existing LINAC vaults can change that.
Medical Devices & Diagnostics
Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
Inhalers are getting smarter, but complexity can backfire. Phillips Medisize is betting DPI success starts with patient-centric design.
Medical Devices & Diagnostics
Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Medical Devices & Diagnostics
Could Co-Diagnostics’ Saudi manufacturing move strengthen its molecular diagnostics strategy?
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.